

# PROGRAMME



# Biofit

FOSTERING  
INNOVATION  
& TRANSFER

The leading European partnering event  
for early-stage deals and investment  
rounds in the Life Sciences field



NEW DESTINATION

# MARSEILLE

FRANCE

8<sup>th</sup> edition

DECEMBER  
**10 & 11**  
2 0 1 9

[www.biofit-event.com](http://www.biofit-event.com)

 @BIOFIT\_EVENT

# BIOFIT AT A GLANCE

BioFIT is both the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovation deals and the European marketplace for pre-seed, seed and Series A investment rounds in the **Life Sciences** field.



## WHO WILL YOU MEET?



# STEERING COMMITTEE

## PHARMA, BIOTECH

- Maria Bobadilla**  
SENIOR DIRECTOR, EXTENDING INNOVATION NETWORK, **ROCHE** 🇫🇷
- Adrian Carter**  
CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, **BOEHRINGER INGELHEIM** 🇩🇪
- Sami Chtourou**  
EXECUTIVE VICE PRESIDENT INNOVATION & SCIENTIFIC AFFAIRS, **LFB** 🇫🇷
- Florence Dal Degan**  
R&D INNOVATION SOURCING DIRECTOR, **NOVO NORDISK** 🇩🇪
- Guy Hélin**  
CEO, **SYNGULON** 🇫🇷
- Stephan Lensky**  
CHIEF OPERATING AND CHIEF BUSINESS OFFICE, **EPIMAB BIOTHERAPEUTICS** 🇫🇷
- Sabrina Lesage**  
STRATEGIC ALLIANCES MANAGER, **PFIZER** 🇫🇷
- Sara Nunez-Garcia**  
SENIOR DIRECTOR, **ROIVANT SCIENCES** 🇫🇷
- Marie-Ange N'Zoutani**  
DIRECTOR, EXTERNAL INNOVATION DRUG DISCOVERY, BUSINESS DEVELOPMENT & LICENSING, **SANOFI** 🇫🇷
- Frédéric Scaërou**  
SENIOR DIRECTOR, HEAD OF EXTERNAL INNOVATION EUROPE AND ASIA, **IPSEN INNOVATION** 🇫🇷
- Joachim Vogt**  
DIRECTOR, SEARCH AND EVALUATION, WESTERN EUROPE, **ABBVIE** 🇩🇪
- Nadine Weisslinger-Darmon**  
MEDICAL DIRECTOR SPECIALTY PRODUCTS, CLINICAL RESEARCH AND ACADEMIC ALLIANCES, **GSK** 🇫🇷

## ACADEMIA, TTOs

- Hervé Ansanay**  
OPERATIONS DIRECTOR, **SATT AXLR** 🇫🇷
- Jürgen Bauer**  
DEPUTY MANAGING DIRECTOR, **EMBLEM TECHNOLOGY TRANSFER** 🇩🇪
- Garold Breit**  
CEO, **BREIT IDEAS LLP** 🇫🇷
- Jean-Luc Chagnaud**  
HEALTHCARE BUSINESS DEVELOPMENT MANAGER & INTELLECTUAL PROPERTY MANAGER, **AQUITAINE SCIENCE TRANSFERT** 🇫🇷
- Anthony Daccache**  
BUSINESS DEVELOPER, **SATT NORD** 🇫🇷
- Caroline Dreyer**  
PRESIDENT, **SATT CONECTUS** 🇫🇷
- Lilla Farkas**  
HEAD, OFFICE OF THE MANAGING DIRECTOR, RESEARCH COORDINATOR, **MPI-CBG, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS** 🇩🇪
- Esther Lange**  
INDUSTRY LIAISON MANAGER, **ASCENION** 🇩🇪

## INVESTORS

- Frank Hensel**  
PRINCIPAL, **HIGH-TECH GRÜNDERFONDS** 🇩🇪
- Jérôme Majoie**  
GENERAL MANAGER, **FOUNDATION FOURNIER-MAJOIE** 🇫🇷
- Anta Gkelou**  
ANALYST, **SOFINNOVA PARTNERS** 🇫🇷
- Lotfi Yelles Chaouche**  
PARTNER, **THEODORUS FUND** 🇫🇷

## ASSOCIATIONS, CLUSTERS & LAW FIRMS

- Nicolas Carboni**  
PRESIDENT, **RÉSEAU C.U.R.I.E.** 🇫🇷
- Barbara Freischem**  
MANAGING DIRECTOR, **EBE - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES** 🇫🇷
- Yohan Grosjean**  
COMMUNICATION OFFICER, **AFFSI - THE FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES** 🇫🇷
- Jean-Louis Hunault**  
PRESIDENT, **SIMV - THE FRENCH ASSOCIATION OF THE ANIMAL HEALTH INDUSTRY** 🇫🇷
- Marco Pintore**  
GENERAL MANAGER, **BIOVALLEY FRANCE** 🇫🇷
- Christian Policard**  
MEMBER OF THE BOARD, CHAIRMAN OF THE BUSINESS DEVELOPMENT SUB-COMMITTEE, **FRANCE BIOTECH** 🇫🇷
- Emilie Royere**  
GENERAL MANAGER, **EUROBIOMED** 🇫🇷
- Cécile Théard-Jallu**  
PARTNER ATTORNEY, **DE GAULLE FLEURANCE & ASSOCIÉS** 🇫🇷
- Etienne Vervaecke**  
GENERAL MANAGER, **EURASANTÉ & NHL CLUSTER** 🇫🇷

# THEY TRUSTED US IN 2018

## PHARMA

AbbVie | Bayer Healthcare | Boehringer Ingelheim  
| GSK | J&J Innovation | Lilly | Merck | MSD |  
Novo Nordisk | Pfizer | Roche | Sanofi | Santen |  
Sumitomo Dainippon Pharma...

## VETERINARY

Bayer Animal Health | Boehringer Ingelheim Animal  
Health | Ceva Animal Health | MSD Animal Health |  
Vetoquinol | Virbac | Zoetis...

## BIOTECH

Biogazelle | Genfit | LFB | LNC Therapeutics | Oxurion  
(former ThromboGenics) | Syngulon | TiGenix...

## TTOs AND ACADEMIA

Ascenion | CNRS | EMBLEM | Imperial Innovations  
| INRA | LifeArc | Max Planck Institute | NIH |  
Princeton University | University of Birmingham...

## INVESTORS

(PRE-SEED, SEED, SERIES A)

Andera Partners | Fund+ | Gimv | High-Tech  
Gründerfonds | Julz Co | Medicxi | MS Ventures |  
Sofinnova Partners | Truffle Capital | TVM Capital...

# 2019 SPONSORS

## SILVER SPONSORS



## BRONZE SPONSORS



## CONTRIBUTING SPONSOR



# PARTNERING

## 48 hours to meet your future project partners, obtain funding and accelerate innovation

- 1** **LOG IN** to the partnering platform and **IDENTIFY** today's innovative products, technologies, licensing opportunities as well as potential project partners.
- 2** **REQUEST** and **PRE-SCHEDULE** one-to-one meetings with the most qualified players in the Life Sciences field.
- 3** **MEET** your future partners and **DEVELOP** new collaboration and partnerships.



Partnering at BioFIT is powered by  **inova**

# PITCH SESSIONS

## The early-stage innovations you need

The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects, licensing opportunities and services in order to foster partnerships and business development in the Life Sciences field.

### START-UP SLAMS

The Start-up Slams are a great opportunity for **young companies** (and particularly start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.  
Pitch fees: Free for all BioFIT registrants.

Sponsored by:



### COLLABORATIVE AND LICENSING OPPORTUNITY PRESENTATIONS

The Collaborative and Licensing Opportunity Presentations are a great opportunity for **TTOs, universities, research institutes and companies** to showcase their early-stage assets in front of potential partners, in order to entail a collaborative project and/or an opportunity to out-license.  
Pitch fees: Free for all BioFIT registrants.

### SERVICE PRESENTATIONS

The Service Presentations are a great opportunity for **service providers and technology platforms with an innovative offer** to showcase their offers in front of potential clients.  
Pitch fees: From €200 to €350 additional fees to the registration fees if selected.

### HOW DOES IT WORK?



# WOULD-BE CEO

## Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO?

As talented CEOs are frequently sought-after by many actors of the biotech industry, this Would-be CEO session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this important issue.


Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly the Would-be CEO session. Any incubator or tech transfer entity looking for an entrepreneur to lead their start-up projects is also welcome to join.

### Bioentrepreneurs workshop:

- Panorama of European entrepreneurial training programmes
- How I met my co-entrepreneur?

### Networking cocktail:

This networking moment will be the occasion to establish collaborations between future entrepreneurs and projects in need of CEOs.



# HOSTED EVENT

## R&D DATING FOR ANIMAL HEALTH AND INNOVATION

DECEMBER 10<sup>TH</sup> & 11<sup>TH</sup>, 2019



BioFIT 2019 will host the 5<sup>th</sup> edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal health-care industry (SIMV)’s initiative, on December 10<sup>th</sup> and 11<sup>th</sup>, 2019 in Marseille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

### Animal health-related roundtable discussions during BioFIT:

- How is the digitalisation transforming the animal health industry?
- Cross-sectorial success stories: Fruitful collaborations between animal and human health sectors

Organised by:



 [simv.org](http://simv.org)

Contact: [secretariat@simv.org](mailto:secretariat@simv.org)

# DAY ONE

TUESDAY, DECEMBER 10<sup>TH</sup>

	Conferences and roundtable discussions	Pitch sessions	Partnering
8.30 am - 9.00 am	NAME BADGE PICKUP & WELCOME COFFEE		
9.00 am - 10.30 am	On which bases does the pharma decide to get involved in the Venture Capital arena?	What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?	Collaborative and Licensing Opportunity Presentations
			One-to-one meetings
10.30 am - 11.00 am	NETWORKING BREAK		
11.00 am - 12.30 pm	<b>PLENARY SESSION</b> What is pharma looking for nowadays? Collaboration and licensing opportunities pharma is looking for, while changing from a drug developer to a healthcare solution provider		
12.30 pm - 2.00 pm	LUNCH		
2.00 pm - 3.30 pm	How can big data fuel collaborations between pharma and academic institutions?	How to value an early-stage though promising asset?	Which funding models to accelerate anti-parasitic and anti-infectious innovation?
			Start-up Slams
			One-to-one meetings
3.30 pm - 4.00 pm	NETWORKING BREAK		
4.00 pm - 5.30 pm	Managing pre-competitive collaboration in Life Sciences: Testimonials on outcomes, limits, constraints and benefits of European consortia.	Challenging conventional wisdom: Is early-stage capital as satisfyingly available in Europe as we like to believe?	Service Presentations
6.15 pm	BIOPARTY		

# DAY TWO

WEDNESDAY, DECEMBER 11<sup>TH</sup>

	Conferences and roundtable discussions	Pitch Sessions	Partnering
8.30 am - 9.00 am	WELCOME COFFEE		
9.00 am - 10.30 am	What are the key questions an academic project should address to ensure a valuable licensing deal in the view of pharmaceutical industries?	What are the recent successful industry-academia collaborations in Artificial Intelligence?	Start-up Slams
10.30 am - 11.00 am	NETWORKING BREAK		
11.00 am - 12.30 pm	What's hot, what's not? What's on the investors' wishlist for 2020?	Animal health R&D: How are the sector's stakeholders changing their core models towards providing complete animal healthcare solutions?	Would-be CEO Workshop: Panorama of European entrepreneurial training programmes - How I met my co-entrepreneur?
			Collaborative and Licensing Opportunity Presentations
			One-to-one meetings
12.30 pm - 2.00 pm	LUNCH		
2.00 pm - 3.30 pm	How to shape the corporate governance of biotechs at their very first steps to make them bankable?	Which new forms of academia-industry partnerships to create seed and pre-seed tools?	Start-up Slams
3.30 pm - 4.00 pm	NETWORKING BREAK		
4.00 pm - 5.30 pm	What do TTOs want to ensure the creation of a viable spinout opportunity?	How is the digital transformation evolving the animal health industry?	Award Ceremony



**TRACK 1**  
Best practices in academia-industry R&D collaborations



**TRACK 2:**  
Nurturing and licensing early-stage assets



**TRACK 3:**  
Early-stage innovation: Identify the right funding sources



**ANIMAL HEALTH**

# CONFERENCE PROGRAMME

## 1 TRACK

### Best practices in academia- industry R&D collaborations

## 2 TRACK

### Nurturing and licensing early-stage assets

## 3 TRACK

### Early-stage innovation: Identify the right funding sources

## PLENARY SESSION

### WHAT IS PHARMA LOOKING FOR NOWADAYS? COLLABORATION AND LICENSING OPPORTUNITIES PHARMA IS LOOKING FOR, WHILE CHANGING FROM A DRUG DEVELOPER TO A HEALTHCARE SOLUTION PROVIDER

A lot of pharma companies declare that they no longer want to be purely developers of drugs, and thus they progressively transition to become healthcare solution providers, trying to seek broader solutions to answer the patient needs, and changing the way they look at assets: What does it mean for the industry in terms of orientation of their scouting efforts, particularly for early-stage assets? This session aims to understand pharma's viewpoint, the consequences for the orientation of deals, the way it is going to influence the relationships with academia and biotech start-ups. How does this strategic intention modify the type and the nature of deals that pharma have with start-ups & academic institutions? How is it affecting early-stage licensing deals?

## 1 TRACK

### Best practices in academia- industry R&D collaborations

#### WHAT ARE THE OUTCOMES OF LONG-LASTING COMMITMENT BETWEEN UNIVERSITIES AND PHARMACEUTICAL COMPANIES?

To which needs do these numerous collaboration schemes answer? What are the specificities of these agreements in terms of management models and R&D means mutualisation. Are short-term reports and industry constraints coherent with multi-years academic agreements?

#### HOW CAN BIG DATA FUEL COLLABORATIONS BETWEEN PHARMA AND ACADEMIC INSTITUTIONS?

How to ensure the full transparency and compliance in the use of academic-origin data in order to abide by ethics? How can consolidating and mutualising data between industrial and academic players unlock the full potential of these partnerships?

#### WHAT ARE THE RECENT SUCCESSFUL INDUSTRY-ACADEMIA COLLABORATIONS IN ARTIFICIAL INTELLIGENCE?

What are the good examples of partnerships in this field? How have they proved to be fertile in innovation for the benefit of both parties?

#### MANAGING PRE-COMPETITIVE COLLABORATION IN LIFE SCIENCES: TESTIMONIALS ON OUTCOMES, LIMITS, CONSTRAINTS AND BENEFITS OF EUROPEAN CONSORTIA.

Which research topics are considered good candidates for competitive consortia at the time of precision medicine? Are the current collaborative models (IMI, H2020...) adapted to the research needs? How to balance each party's interests and define the domain of precompetitive research. How can IP problematics be managed?

#### TO WHAT EXTENT ARE PATIENT ORGANISATIONS QUALIFYING AS A PARTNER WHEN COLLABORATING WITH PHARMA AND ACADEMIA?

Everybody wants an increasing commitment of patient organisations in collaborative projects in healthcare, as they bring background, knowledge and real-life evaluation to the table. How do they influence the way collaborations are carried? How do they participate to R&D financing efforts? How to capitalise on patient organisations' legitimacy as real life evaluation experts?

## 2 TRACK

### Nurturing and licensing early-stage assets

#### **HOW TO VALUATE AN EARLY-STAGE THOUGH PROMISING ASSET?**

To what extent do experimented actors help the bio-entrepreneur to aim for a realistic maturation and validation roadmap? How do they help the managing team to understand value inflection points? How do the industry players (pharma, biotech, VC) handle this issue of granting of value to those assets? How industrial players could help academic institutions and TTOs avoid making mistakes at the very early development stages?

#### **WHAT ARE THE KEY QUESTIONS AN ACADEMIC PROJECT SHOULD ADDRESS TO ENSURE A VALUABLE LICENSING DEAL IN THE VIEW OF PHARMACEUTICAL INDUSTRIES?**

How can a biotech company prepare for a due diligence by big pharma? Which areas are usually underestimated when preparing for a due diligence? What is an efficient due diligence plan? How to prepare an attractive asset to pharma and investors? What are the fundamentals of Due diligence? What are the legal aspects to get prepared to?

#### **WHICH NEW FORMS OF ACADEMIA-INDUSTRY PARTNERSHIPS TO CREATE SEED AND PRE-SEED TOOLS?**

Numerous tools have been created in the last years, how do these early-stage financing vehicles work? On which bases do they ground funds allocation? What are the expectations of the limited partners? Who are the players involved in such investment tools, and what do they await from their involvement in such early-stage funding and investment tools?

#### **WHAT DO TTOS WANT TO ENSURE THE CREATION OF A VIABLE SPINOUT OPPORTUNITY?**

What does viable mean for TTOs, and do we have the same definition everywhere around Europe? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?

## 3 TRACK

### Early-stage innovation: Identify the right funding sources

#### **WHAT'S HOT, WHAT'S NOT? WHAT'S ON THE INVESTORS' WISHLIST FOR 2020?**

How do the deals and lessons-learned from 2019 investment let us peak at what can be expected for 2020? What are the tips for success for next year? Which therapeutic area will gain or reinforce interest from the VCs? How can you make sure that your business will be on VC's radar?

#### **ON WHICH BASES DOES THE PHARMA DECIDE TO GET INVOLVED IN THE VENTURE CAPITAL ARENA?**

Whether that 'd be as a limited partner of a firm, or creating its own corporate venture tool, what are the expectations of pharma to get involved in financing?

#### **HOW TO SHAPE THE CORPORATE GOVERNANCE OF BIOTECHS AT THEIR VERY FIRST STEPS TO MAKE THEM BANKABLE?**

How to cope with a pre-established governance from an academic spin-off? How can clashes of culture between researchers and industrials be beneficial and craft a balanced managing team? How are VCs expressing their demands and expectations and how are they filled up? To what extent is leaning on international strategic and scientific committees as soon as they are born a recipe of success?

#### **CHALLENGING CONVENTIONAL WISDOM: IS EARLY-STAGE CAPITAL AS SATISFYINGLY AVAILABLE IN EUROPE AS WE LIKE TO BELIEVE?**

How is it crucial to question the accepted common idea that Europe only lacks bigger funds for bigger roundtables and for more mature companies? Compared to European later-stage investment markets which are positively underfunded, it seems at first glance that the early-stage capital market is healthy and well-fuelled, but is it genuinely the case? Is the European early-stage capital market as rich in players and capital as it is said to be?

#### **WHICH FUNDING MODELS TO ACCELERATE ANTI-PARASITIC AND ANTI-INFECTIOUS INNOVATION?**

Which funding to support new vaccines, drugs and treatment strategies in Africa? What is the role of philanthropic funding? How can foundations and governments form alliances to fund better R&D?

# ORGANISERS



Eurasanté is an incubator, a technology transfer tool and a cluster manager in the biotech, medtech, nutrition and healthcare fields in Northern France. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects.

The regional network includes over 1,000 companies working in Life Sciences and Healthcare. The Health field in the Hauts-de-France region has a total of 30,800 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories. Eurasanté also organises four international partnering events intended to increase and improve interaction between academia and industry: BioFIT, NutrEvent, MedFIT, AgeingFit.

[www.eurasante.com](http://www.eurasante.com) @Eurasante

# ORGANISERS



Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory's structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow's health technologies.

[www.biovalley-france.com](http://www.biovalley-france.com) @BioValleyFrance



The Nutrition Health Longevity (NHL) Cluster is a dynamic network at the intersection of health, biotechnology and nutrition. The NHL Cluster aims to connect academia and industry partners around R&D projects. It focuses on the prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

[www.nhl-cluster.com](http://www.nhl-cluster.com) @PoleNSL



Founded in 2009 by regional stakeholders, EUROBIOMED is a Life Science cluster based in Southern France. Over 285 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities are members. We lead regional initiatives and help our member businesses and research institutes to innovate, finance, develop and achieve their scientific and business objectives to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centres, start-ups and industrial success stories. Among Eurobiomed's main assets are the number of people involved, the quality of the network and the mutual trust of its members, which reinforces interactions and facilitates cooperation.

[www.eurobiomed.com](http://www.eurobiomed.com) @PoleEurobiomed

# JOIN BIOFIT 2019

# SPONSORS & PARTNERS

## REGISTRATION FEES (excl. VAT)

### REGISTRATION FEES

Fees per person | (excl. VAT)

	<b>SUPER EARLY BIRD</b> Before March 29 <sup>th</sup> , 2019 included	<b>EARLY BIRD</b> From March 30 <sup>th</sup> to June 28 <sup>th</sup> , 2019 included	<b>REGULAR FEE</b> From June 29 <sup>th</sup> to November 4 <sup>th</sup> , 2019 included	<b>LATE REGISTRATION</b> From November 5 <sup>th</sup> , 2019
<b>Mature company</b> (> 5 years old)	€ 1,032	€ 1,199	€ 1,349	€ 1,484
<b>Investor</b> (pre-seed, seed or Series A)	€ 1,032	€ 1,199	€ 1,349	€ 1,484
<b>Cluster   Association</b>	€ 879	€ 1,022	€ 1,149	€ 1,264
<b>TTO   Research institution</b>	€ 688	€ 799	€ 899	€ 999
<b>Emerging company</b> (≤ 5 years old) or <b>SME</b> (≤ 5 employees)	€ 420	€ 488	€ 549	€ 604
<b>Academic scientist</b>	€ 344	€ 399	€ 449	€ 494

## EXHIBITION FEES (excl. VAT)

### EXHIBITION FEES

(excl. VAT)

	<b>SUPER EARLY BIRD</b> Before March 29 <sup>th</sup> , 2019 included	<b>EARLY BIRD</b> From March 30 <sup>th</sup> to June 28 <sup>th</sup> , 2019 included	<b>REGULAR FEE</b> From June 29 <sup>th</sup> to November 4 <sup>th</sup> , 2019 included
<b>6 m<sup>2</sup> equipped stand + 1 full pass</b>	€ 2,200	€ 2,400	€ 2,600
<b>9 m<sup>2</sup> equipped stand + 1 full pass</b>	€ 3,300	€ 3,500	€ 3,700
<b>12 m<sup>2</sup> equipped stand + 1 full pass</b>	€ 4,400	€ 4,600	€ 4,800
<b>18 m<sup>2</sup> equipped stand + 2 full passes</b>	€ 6,600	€ 6,800	€ 7,000

## SPONSORSHIP PACKAGES (excl. VAT)



**Gold Sponsor**  
€ 15,500



**Silver Sponsor**  
€ 11,000



**Bronze Sponsor**  
€ 6,500

Please contact us for other sponsorship opportunities.

## SPONSORS



## SUPPORTERS



## MEDIA PARTNERS





## Marseille

### One of the best innovative hubs for biotech in Europe

The Aix-Marseille-Provence Metropolis and the Sud Provence-Alpes-Côte d'Azur Region are a dynamic hotbed for biotech and pharma innovations, providing unrivalled assets and cutting edge resources. This is due in particular to its leading research and training centres, its incubators which boost R&D projects, Eurobiomed, the cluster which supports innovations' development all along their development and its dedicated network including clusters, industries, SMEs and start-ups.

#### Event Venue

PARC CHANOT  
114, Rond-Point du Prado  
13008 Marseille, France

#### General Enquiries

Margaux Satola  
msatola@eurasanté.com  
+33 (0)3 59 39 01 82

#### Conference Programme

Claire Lesnik  
clesnik@eurasanté.com  
+33 (0)3 59 39 01 87

#### Organisers:



#### Institutional Partners:

